A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1340-1345

  Xie, Wenjie ^a   He, Yan ^b   Huo, Da ^b   Huang, Yafang ^b   Wu, Wei ^b  

^a United Laboratories International Holdings Limited   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; MAP kinases; p21 waf1; Prolactin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROLACTIN DERIVATIVE; PROTEIN P21; S 179 D PRL; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROLACTIN; PROMOTER REGIONS, GENETIC; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION; VITAMIN D RESPONSE ELEMENT;

EID: 79951757206     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9386-6     Document Type: Article

References (28)

1. Ueda EK, Soares CR, Bartolini P, DeGuzman A, Lorenson MY, Walker AM. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin. Biochemistry. 2009;48:6887-97.
2. Wu W, Coss D, Lorenson MY, Kuo CB, Xu X, Walker AM. Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry. 2003;42:7561-70. (Pubitemid 36735833)
3. Kuo CB, Wu W, Xu X, Yang L, Chen C, Coss D, et al. Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes beta-casein gene expression in the rat mammary gland. Cell Tissue Res. 2002;309:429-37. (Pubitemid 34994880)
4. Lee EJ, Moon GS, Choi WS, Kim WJ, Moon SK. Naringininduced p21 waf1-mediated G (1)-phase cell cycle arrest via activation of the Ras/Raf/ERK signaling pathway in vascular smooth muscle cells. Food Chem Toxicol. 2008;46:3800-7.
5. Luo Y, Hurwitz J, Massague J. Cell cycle inhibition by independent CDK and PCNA binding domains in p21 Cip1. Nature. 1995;375:159-61.
6. Wu W, Chen YH, Ueda E, Tan DY, Bartolini P, Walker AM. Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol Res. 2006;16:75-84.
7. Wang Q, Lee D, Chandraratna RAS, Sysounthone V, Christakos S, Korah R, et al. 1, 25-Dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat. 2001;67:157-68. (Pubitemid 32744496)
8. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002;9:45-59. (Pubitemid 34298363)
9. Chouvet C, Berger U, Coombes R. 1, 25-Dihydroxyvitamin, D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF7, BT-20). J Steroid Biochem. 1986;24:373-6. (Pubitemid 16047809)
10. Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L. Sensitivity to growth suppression by 1alpha, 25-dihydroxyvitamin D (3) among MCF-7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol. 2002;81:123-33. (Pubitemid 34876403)
11. Gaschott T, Wachtershauser A, Steinhiber D, Stein J. 1, 25-Dihydroxycholecalciferol enhances butyrate-induced p21 (Waf1/Cip1) expression. Biochem Biophys Res Commun. 2001;283:80-5. (Pubitemid 32912539)
12. Liu M, Lee MH, Cohen M, Bommakanti M, Freeman LP. Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10:142-53. (Pubitemid 26049905)
13. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, et al. 1, 25-Dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat. 2001;67:157-68. (Pubitemid 32744496)
14. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr-Relat. Cancer. 2002;9:45-59. (Pubitemid 34298363)
15. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat. 1994;31:191-202. (Pubitemid 24323461)
16. Mezzetti G, Barbiroli B, Oka T. 1, 25-Dihydroxycholecalciferol receptor regulation in hormonally induced differentiation of mouse mammary gland in culture. Endocrinology. 1987;120:2488-93. (Pubitemid 17084925)
17. Colston K, Berger U, Wilson P, Hadcocks L, Naeem I, Earl H, et al. Mammary gland 1, 25-dihydroxyvitamin D3 receptor content during pregnancy and lactation. Mol Cell Endocrinol. 1988;60:15-22.
18. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology. 1998;139:609-16. (Pubitemid 28513210)
19. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology. 2003;144:5300-7. (Pubitemid 37476058)
20. Davis D, Pintucci G, Stern A. MAPK-dependent expression of p21 waf1 and p27 kip1 in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000;472:50-2. (Pubitemid 30224584)
21. Liu Y, Martindale JL, Gorospe M, Holbrook NJ. Regulation of p21 waf1/cip1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 1996;56:31-5.
22. Lessor T, Yoo JY, Hamburger AW. Regulation of heregulin beta-1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. J Cell Biochem. 1998;70:587-95. (Pubitemid 28357967)
23. Ho TC, Chen SL, Yang YC, Chen CY, Feng FP, Hsieh JW, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPS and p53. J Biol Chem. 2008;283:30273-88.
24. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 waf1/cip1 mediated by STAT1. Science. 1996;272:719-22.
25. Wyszomierski SL, Yeh J, Rosen JM. Glucocorticoid receptor/signal transducer and activator transcription 5 (STAT5) interactions enhances STAT5 activation by prolong STAT5 DNA binding and tyrosine phosphorylation. Mol Endocrinol. 1999;13:330-43. (Pubitemid 29068007)
26. Barsony J, Pike JW, DeLuca HF, Marx SJ. Immunocytology with microwave-fixed fibroblasts shows 1 alpha, 25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. Cell Biol. 1990;111:2385-95. (Pubitemid 120014523)
27. Wu W, Ginsburg E, Vonderhaar BK, Walker AM. S179D prolactn increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. 2005;65:7509-15. (Pubitemid 41161287)
28. Huang KT, Walker AM. Long term increased expression of the short form 1b prolactin receptor in PC3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity. Prostate. 2009;8:37-47.